Previously dba Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis and pain, in October 2018, management announced a name change to Adhera Therapeutics, Inc. with the new ticker designation ATRX. The new name rbetter describes the companys mission to develop and commercialize unique pharmaceutical therapies and leverage technology to improve patient outcomes. The firm had been organized around treating the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. Their first FDA approved drug, Prestalia®, contains perindopril arginine, an ACE inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension to lower blood pressure. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company's 'next-generation of celecoxib,' including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic. Additionally we are developing therapeutic microbiome using the only orally bioavailable siRNAs platform against FAP and IBD.
